Pascal Demoly

Summary

Country: France

Publications

  1. ncbi [Drug allergies: management and current aspects]
    P Demoly
    Clinique des Maladies Respiratoires, Hopital Arnaud de Villeneuve, Montpellier
    Presse Med 27:1406-11. 1998
  2. ncbi [ERAP, a pharmaco-epidemiologic survey on perennial allergic rhinitis in every day medical practice in France]
    Pascal Demoly
    Service des Maladies Respiratoires, INSERM U454 IFR3, Hopital Arnaud de Villeneuve, CHU de Montpellier, 34
    Presse Med 32:1066-73. 2003
  3. ncbi [Allergy to macrolides. 21 cases]
    P Demoly
    Maladies Respiratoires, Hôpital Amaud de Villeneuve, Montpellier
    Presse Med 29:294-8. 2000
  4. ncbi [Allergy to macrolide antibiotics. Review of the literature]
    P Demoly
    INSERM U454 IFR3, Hôpital Amaud de Villeneuve, CHU de Montpellier
    Presse Med 29:321-6. 2000
  5. ncbi [Asthma and rhinitis medications: pregnancy precautions]
    P Demoly
    INSERM U454, IFR3, Hopital Arnaud de Villeneuve, CHU de Montpellier
    Presse Med 29:1625-9. 2000
  6. ncbi [Genetics of asthma and atopy]
    P Demoly
    Maladies Respiratoires, INSERM U454, Hopital Arnaud de Villeneuve, CHU de Montpellier
    J Soc Biol 194:39-42. 2000
  7. ncbi [From allergic rhinitis to sinus diseases (sinusitis/nasal polyps): epidemiologic and experimental links]
    P Demoly
    Maladies Respiratoires, INSERM U454, IFR3, Hopital Arnaud de Villeneuve, Service d ORL, Hopital Gui de Chauliac, CHU de Montpellier
    Rev Mal Respir 17:925-30. 2000
  8. ncbi Epidemiology of drug allergy
    P Demoly
    Maladies Respiratoires, INSERM U454 IFR3, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier, France
    Curr Opin Allergy Clin Immunol 1:305-10. 2001
  9. ncbi [Diagnosis of drug allergy]
    P Demoly
    Maladies Respiratoires, INSERM U454 IFR3, Hopital A de Villeneuve, CHU de Montpellier, France
    Rev Mal Respir 19:260-2. 2002
  10. ncbi Anaphylaxis to antitetanus toxoid serum
    P Demoly
    Maladies Respiratoires, INSERM U454, Hopital Arnaud de Villeneuve, CHU de Montpellier, 34295 Montpellier Cedex 5, France
    Allergy 57:860-1. 2002

Collaborators

Detail Information

Publications124 found, 100 shown here

  1. ncbi [Drug allergies: management and current aspects]
    P Demoly
    Clinique des Maladies Respiratoires, Hopital Arnaud de Villeneuve, Montpellier
    Presse Med 27:1406-11. 1998
    ..Allergic reactions are unpredictable reactions related to immunologic mechanism. Pseudoallergic reactions mimic allergic reactions but no drug-specific antibody or T cell proliferation can be demonstrated...
  2. ncbi [ERAP, a pharmaco-epidemiologic survey on perennial allergic rhinitis in every day medical practice in France]
    Pascal Demoly
    Service des Maladies Respiratoires, INSERM U454 IFR3, Hopital Arnaud de Villeneuve, CHU de Montpellier, 34
    Presse Med 32:1066-73. 2003
    ..In order to gain knowledge on the management of perennial allergic rhinitis by the practitioners in France, a survey (Enquête épidémiologique sur la rhinite allergique per-annuelle en pratique quotidienne--ERAP) was developed...
  3. ncbi [Allergy to macrolides. 21 cases]
    P Demoly
    Maladies Respiratoires, Hôpital Amaud de Villeneuve, Montpellier
    Presse Med 29:294-8. 2000
    ..Allergic drug reactions to macrolides are extremely rare and there is little information in the literature concerning relevant diagnostic tests...
  4. ncbi [Allergy to macrolide antibiotics. Review of the literature]
    P Demoly
    INSERM U454 IFR3, Hôpital Amaud de Villeneuve, CHU de Montpellier
    Presse Med 29:321-6. 2000
    ..It would appear that macrolide allergies are unlikely to be class allergies. This is important as eviction advice could be limited to the single causal macrolide...
  5. ncbi [Asthma and rhinitis medications: pregnancy precautions]
    P Demoly
    INSERM U454, IFR3, Hopital Arnaud de Villeneuve, CHU de Montpellier
    Presse Med 29:1625-9. 2000
    ..Indeed, it would be regrettable to be too prudent and deprive symptomatic patients of active treatments. Patients should be clearly informed of the benefits and risks of drug therapy...
  6. ncbi [Genetics of asthma and atopy]
    P Demoly
    Maladies Respiratoires, INSERM U454, Hopital Arnaud de Villeneuve, CHU de Montpellier
    J Soc Biol 194:39-42. 2000
    ..Much of the information available today has been fragmentary and not always confirmed. Alleles at multiple loci are likely to be involved and the ultimate picture is most likely determined by many genetic and environmental factors...
  7. ncbi [From allergic rhinitis to sinus diseases (sinusitis/nasal polyps): epidemiologic and experimental links]
    P Demoly
    Maladies Respiratoires, INSERM U454, IFR3, Hopital Arnaud de Villeneuve, Service d ORL, Hopital Gui de Chauliac, CHU de Montpellier
    Rev Mal Respir 17:925-30. 2000
    ..Because the diagnosis of allergic rhinitis provides useful therapeutic options, an appropriate evaluation for underlying allergies in indicated in any patient with chronic upper respiratory tract symptoms...
  8. ncbi Epidemiology of drug allergy
    P Demoly
    Maladies Respiratoires, INSERM U454 IFR3, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier, France
    Curr Opin Allergy Clin Immunol 1:305-10. 2001
    ..Therefore, there are few true epidemiological data, and most of those that are available, including incidence, mortality and socioeconomic impact data, should be interpreted with caution...
  9. ncbi [Diagnosis of drug allergy]
    P Demoly
    Maladies Respiratoires, INSERM U454 IFR3, Hopital A de Villeneuve, CHU de Montpellier, France
    Rev Mal Respir 19:260-2. 2002
  10. ncbi Anaphylaxis to antitetanus toxoid serum
    P Demoly
    Maladies Respiratoires, INSERM U454, Hopital Arnaud de Villeneuve, CHU de Montpellier, 34295 Montpellier Cedex 5, France
    Allergy 57:860-1. 2002
  11. ncbi Asthma therapy during pregnancy
    Pascal Demoly
    Exploration des Allergies Maladies Respiratoires INSERM U454, Hopital Arnaud de Villeneuve, Institut Universitaire de Recherche Clinique de Montpellier, University Hospital of Montpellier, 34295 Montpellier Cedex 5, France
    Expert Opin Pharmacother 4:1019-23. 2003
    ..Usually, there is at least one 'safe' drug from each major class used to control symptoms. We will review the current literature on this subject...
  12. ncbi [Identifying and understanding drug allergies]
    Pascal Demoly
    Inserm U 454 IFR3, Hopital Arnaud de Villeneuve, Avenue Gaston Giraud, 34295 Montpellier, France
    Med Sci (Paris) 19:327-36. 2003
    ....
  13. ncbi [Respiratory allergic disease genes]
    P Demoly
    Service des Maladies Respiratoires, Inserm U 454 IFR3, Hopital Arnaud de Villeneuve, CHU de Montpellier, 34295 Montpellier Cedex 5
    Rev Pneumol Clin 59:67-75. 2003
    ..Research will continue to define these genes more precisely or to recognize others and to apply this knowledge to therapeutic and diagnostic applications...
  14. ncbi Treatment of allergic rhinitis during pregnancy
    Pascal Demoly
    Department of Respiratory Medicine, INSERM U454, Hospital Arnaud de Villeneuve, University Hospital of Montpellier, 34295 Cedex 5 Montpellier, France
    Drugs 63:1813-20. 2003
    ..There are no such data available for intra-nasal decongestants. Finally, pregnancy is not considered as a contraindication for the continuation of allergen specific immunotherapy...
  15. ncbi Successful docetaxel tolerance induction
    D Messaad
    Maladies Respiratoires, INSERM U454, Hopital Arnaud de Villeneuve, CHU de Montpellier, 34295 Montpellier Cedex 5, France
    Allergy 58:1320-1. 2003
  16. ncbi Classification and epidemiology of hypersensitivity drug reactions
    Pascal Demoly
    Allergy Department, Maladies Respiratoires and INSERM U454 IFR3, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, 34295 Montpellier Cedex 5, France
    Immunol Allergy Clin North Am 24:345-56, v. 2004
    ..True epidemiologic data are limited, and most of the available information on the incidence, mortality, and socioeconomic impact should be discussed with caution...
  17. ncbi Update on beta-lactam allergy diagnosis
    Pascal Demoly
    Exploration des Allergies, Maladies Respiratoires, INSERM U454 IFR3, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, 34295 Montpellier Cedex 5, France
    Curr Allergy Asthma Rep 5:9-14. 2005
    ..In this review, we describe the general guidelines for evaluating subjects in whom there is suspicion of allergic reactions to beta-lactams...
  18. ncbi Anaphylactic reactions--value of skin and provocation tests
    Pascal Demoly
    Exploration des Allergies, Maladies Respiratoires, INSERM U454, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, 34295 Montpellier, France
    Toxicology 209:221-3. 2005
    ..These tools are currently being evaluated by the European Network of Drug Allergy, under the aegis of the EAACI drug hypersensitivity group of interest...
  19. ncbi Managing asthma during pregnancy
    Pascal Demoly
    Exploration des Allergies Maladies Respiratoires, INSERM U454, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, 34295 Montpellier Cedex 5, France
    Lancet 365:1212-3. 2005
  20. ncbi The place of spirometry in the diagnosis of asthma in those suffering from allergic rhinitis: a pilot study
    P Demoly
    Exploration des Allergies, Service des Maladies Respiratoires, INSERM U454 IFR3, Hopital Arnaud de Villeneuve, CHU de Montpellier, 34295 Montpellier Cedex 5, France
    Allergy 60:1089-90. 2005
  21. ncbi Comparison of pharmacovigilance algorithms in drug hypersensitivity reactions
    Said Benahmed
    Exploration des Allergies Maladies Respiratoires, INSERM U454 IFR3, Hopital Arnaud de Villeneuve, CHU Montpellier, 34295 Montpellier Cedex 5, France
    Eur J Clin Pharmacol 61:537-41. 2005
    ..A firm diagnosis of drug hypersensitivity, because it may re-induce the reaction, is seldom confirmed. Causality assessment algorithms are therefore of interest...
  22. ncbi The relation between asthma and allergic rhinitis
    Pascal Demoly
    Exploration des Allergies Maladies Respiratoires INSERM U454, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, 34295 Montpellier Cedex 5, France
    Lancet 368:711-3. 2006
  23. ncbi [Drug allergies and drug hypersensitivities]
    Pascal Demoly
    Unité d Exploration des Allergies, maladies respiratoires Inserm, Hopital Arnaud de Villeneuve, CHU de Montpellier, 34295 Montpellier Cedex 5
    Rev Prat 57:1326-30. 2007
    ..Biological tests are being evaluated. When properly performed in specialised centres, a firm diagnosis is often possible and safe alternative medication can be proposed...
  24. doi Safety of intranasal corticosteroids in acute rhinosinusitis
    Pascal Demoly
    Clinical Department of Allergology, Maladies Respiratoires, INSERM U657, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier Cedex 5, France
    Am J Otolaryngol 29:403-13. 2008
    ....
  25. ncbi [Nasal allergy and asthma: one or two diseases?]
    Pascal Demoly
    Maladies Respiratoires, INSERM U454, IFR3, Hopital Arnaud de Villeneuve, CHU de Montpellier, 34295 Montpellier cedex 05
    Bull Acad Natl Med 189:1461-73. 2005
    ....
  26. ncbi Accuracy of a pharmacovigilance algorithm in diagnosing drug hypersensitivity reactions
    Said Benahmed
    Exploration des Allergies, Maladies Respiratoires, and Département d Information Médicale, Hopital Arnaud de Villeneuve, Montpellier, France
    Arch Intern Med 165:1500-5. 2005
    ..This study was performed to evaluate the diagnostic accuracy of a pharmacovigilance algorithm in patients with 1 or more histories suggestive of drug hypersensitivity...
  27. doi Impact of allergic rhinitis symptoms on quality of life in primary care
    Philippe Jean Bousquet
    University Hospital, CHU de Montpellier, Montpellier, France
    Int Arch Allergy Immunol 160:393-400. 2013
    ..Allergic rhinitis (AR) impairs quality of life (QoL), sleep and work. The Allergic Rhinitis and its Impact on Asthma (ARIA) classification is widely used, but the impact of the different symptoms on QoL is not clear...
  28. ncbi [Hypersensitivity to insulin]
    Djamel Messaad
    Exploration des Allergies, Maladies Respiratoires, INSERM U454 IFR3, Hopital Arnaud de Villeneuve, CHU, Montpellier
    Presse Med 33:631-8. 2004
    ..This frequency has decreased from 1 to 55% with non purified insulins and to 0.1 to 2% with newly generated insulins...
  29. ncbi Epidemiology of hypersensitivity drug reactions
    Eva Rebelo Gomes
    Allergy Department, INSERM U454 IFR3, Arnaud de Villeneuve Hospital, University Hospital of Montpellier, Montpellier, France
    Curr Opin Allergy Clin Immunol 5:309-16. 2005
    ..This review summarizes current knowledge on the incidence, prevalence, mortality and risk factors for these reactions in different populations...
  30. doi Budesonide/formoterol maintenance and reliever therapy versus conventional best practice
    Pascal Demoly
    University Hospital of Montpellier and INSERM U, Hopital Arnaud de Villeneuve, France
    Respir Med 103:1623-32. 2009
    ..29; P<0.01) while risk of remaining uncontrolled decreased (25% versus 29%, OR 0.81; P<0.01). Budesonide/formoterol maintenance and reliever therapy improves key aspects of asthma control versus physicians' choice of CBP...
  31. doi Safety of cefuroxime as an alternative in patients with a proven hypersensitivity to penicillins: a DAHD cohort survey
    Silvia Caimmi
    Exploration des Allergies, Clinique des Maladies Respiratoires and INSERM U657, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, 371 Avenue du Doyen Gaston Giraud, Montpellier Cedex 5, France
    Int Arch Allergy Immunol 153:53-60. 2010
    ..In patients sensitized to beta-lactams, a safe beta-lactam alternative is often needed. The objective was to assess the safety of cefuroxime in patients with a proven beta-lactam allergy...
  32. pmc "A year-long, fortnightly, observational survey in three European countries of patients with respiratory allergies induced by house dust mites: Methodology, demographics and clinical characteristics"
    Pascal Demoly
    Allergy Division, Pulmonology Department, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier, France
    BMC Pulm Med 16:85. 2016
    ..However, the fluctuating, pernicious nature of the symptoms has given rise to a perception that HDM-induced respiratory allergy is not a "real" disease...
  33. doi How can we better classify NSAID hypersensitivity reactions?--validation from a large database
    Silvia Caimmi
    Allergy Department and INSERM U657, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier, France
    Int Arch Allergy Immunol 159:306-12. 2012
    ..The aim of the present study was to better classify the many hypersensitivity reactions to NSAIDs...
  34. ncbi Confirmation of the diagnosis of natural rubber latex allergy by the Basotest method
    Marie Laure Hemery
    Unit, Service des Maladies Respiratoires, Hopital Arnaud de Villeneuve, Montpellier, France
    Int Arch Allergy Immunol 136:53-7. 2005
    ..The aim of this study was to evaluate the performance (specificity and sensitivity) of Basotest in the diagnosis of natural rubber latex allergy...
  35. doi The Consolidated Standards of Reporting Trials (CONSORT) Statement applied to allergen-specific immunotherapy with inhalant allergens: a Global Allergy and Asthma European Network (GA(2)LEN) article
    Philippe J Bousquet
    Department of Respiratory Diseases, University Hospital of Montpellier, Montpellier, France
    J Allergy Clin Immunol 127:49-56, 56.e1-11. 2011
    ..Randomized trials provide evidence to inform treatment decisions. The Consolidated Standards of Reporting Trials (CONSORT) Statement is a set of recommendations for the reporting of trials...
  36. ncbi Clinical presentation and time course in hypersensitivity reactions to beta-lactams
    P J Bousquet
    Exploration des Allergies, Service des Maladies Respiratoires, Hopital Arnaud de Villeneuve, University Hospital of Montpellier INSERM U454 IFR3, Hopital Arnaud de Villeneuve, Montpellier, France
    Allergy 62:872-6. 2007
    ..beta-lactam hypersensitivity reactions are classified as immediate or nonimmediate. Diagnosis is usually based upon skin tests and provocation challenges...
  37. doi Important research questions in allergy and related diseases: nonallergic rhinitis: a GA2LEN paper
    J Bousquet
    University Hospital and INSERM, Montpellier, France
    Allergy 63:842-53. 2008
    ..It is likely that neuronal mechanisms, T cells, innate immunity and possibly auto-immune responses all play a role in NAR and may also contribute to the symptoms of allergic rhinitis...
  38. doi Google Trends terms reporting rhinitis and related topics differ in European countries
    Jean Bousquet
    MACVIA France, Contre les MAladies Chroniques pour un VIeillissement Actif en France European Innovation Partnership on Active and Healthy Ageing Reference Site, Montpellier, France
    Allergy . 2017
    ..Using longitudinal data in different countries and multiple terms, we identified an awareness-related spike of searches (December 2016). This article is protected by copyright. All rights reserved...
  39. pmc Management of the polyallergic patient with allergy immunotherapy: a practice-based approach
    Pascal Demoly
    Division of Allergy, Department of Pulmonology, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier, France Sorbonne Universités, UPMC Paris 06, UMR S 1136, IPLESP, Equipe EPAR, Paris, France
    Allergy Asthma Clin Immunol 12:2. 2016
    ..However, management approaches to allergen immunotherapy (AIT) in polysensitized and polyallergic patients are not standardized...
  40. doi Clinical relevance of cluster analysis in phenotyping allergic rhinitis in a real-life study
    Philippe Jean Bousquet
    University Hospital, and INSERM CESP 1018, Montpellier, France
    Int Arch Allergy Immunol 166:231-40. 2015
    ..Disease stratification, using phenotypic characterization performed either by hypothesis- or data-driven methods, was developed to improve clinical decisions. However, cluster analysis has not been used for allergic rhinitis...
  41. ncbi Drug provocation tests in patients with a history suggesting an immediate drug hypersensitivity reaction
    Djamel Messaad
    Hopital Arnaud de Villeneuve, Montpellier, France
    Ann Intern Med 140:1001-6. 2004
    ..Drug hypersensitivity reactions are common and can be life-threatening. Confirmation of the diagnosis should be rigorous and based on clinical history and a physical examination, possibly followed by skin tests and drug provocation tests...
  42. doi Desloratadine for the treatment of cypress pollen-induced allergic rhinitis
    Pascal Demoly
    Allergy Department, INSERM U657, Maladies Respiratoires, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier, France
    Ann Allergy Asthma Immunol 103:260-6. 2009
    ..Few studies have been conducted to assess treatment options for patients with sensitivities to cypress pollens, important triggers of allergic rhinitis (AR) in the Mediterranean region...
  43. ncbi [Allergen-specific immunotherapy or desensitization]
    Pascal Demoly
    Unité d Exploration des Allergies, Maladies Respiratoires, Hopital Arnaud de Villeneuve, CHU de Montpellier et Inserm U657, 34295 Montpellier Cedex 5, France
    Bull Acad Natl Med 193:1127-44; discussion 1144-5. 2009
    ..More information is also needed on patient selection, the treatment duration, and dosing schedules...
  44. doi Update in drug allergy: novel drugs with novel reaction patterns
    Marta Rubio
    Allergy Department and INSERM U657, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier, France
    Curr Opin Allergy Clin Immunol 10:457-62. 2010
    ..This review summarizes current knowledge on the epidemiology, mechanisms, and clinical and in-vitro diagnosis of these reactions...
  45. ncbi [Recommendations for the management of asthma]
    J Bousquet
    Service des Maladies Respiratoires, CHU Monptellier, INSERM U454, Hôpital Arnaud de Villeneuve 34 295 Montpellier
    Rev Prat 51:533-7. 2001
    ..These guidelines are applied in over 100 countries worldwide, and, in countries where they are applied, morbidity and mortality due to asthma have decreased...
  46. ncbi Specific immunotherapy in rhinitis and asthma
    J Bousquet
    Service des Maladies Respiratoires, INSERM U454 Hĵpital Arnaud de Villeneuve, Montepelier, France
    Ann Allergy Asthma Immunol 87:38-42. 2001
    ....
  47. ncbi National survey on the management of rhinopathies in asthma patients by French pulmonologists in everyday practice
    P Demoly
    Maladies Respiratoires, INSERM U454 IFR3, Hopital Arnaud de Villeneuve, University of Montpellier, France
    Allergy 58:233-8. 2003
    ..As part of this new report and prior to its diffusion, we investigated the management of rhinopathies in asthma patients by pulmonologists in their everyday practice...
  48. ncbi Drug hypersensitivities: definition, epidemiology and risk factors
    P Demoly
    Allergy Department, Maladies Respiratoires and INSERM U454, IFR3, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, 34295 Montpellier Cedex 5, France
    Eur Ann Allergy Clin Immunol 37:202-6. 2005
    ..Future progress in genetics can help the identification of populations at risk for specific reactions. This review describes currently known data on incidence,prevalence, mor tality and risk factors of these reactions...
  49. ncbi Drug hypersensitivity: epidemiology and risk factors
    L Guglielmi
    Maladies Respiratoires, INSERM U454 IFR3, Hopital Arnaud de Villeneuve, avenue du Doyen Gaston Giraud, 34295 Montpellier Cedex 5, France
    Curr Pharm Des 12:3309-12. 2006
    ..The chemical properties of the drug and the treatment regimen also influence the development of drug allergies...
  50. ncbi Prospects for a vaccine in allergic diseases and asthma
    J Bousquet
    Hopital Arnaud de Villeneuve, INSERM V454, Montpellier, France
    BioDrugs 13:61-75. 2000
    ..Nonspecific approaches include humanised anti-IgE antibodies,moderation of the T(H)2 cytokine network and antisense oligodeoxynucleotide therapy...
  51. doi Unmet needs in severe chronic upper airway disease (SCUAD)
    Jean Bousquet
    University Hospital, Montpellier, France
    J Allergy Clin Immunol 124:428-33. 2009
    ..This document can also serve to optimize the pharmacoeconomic evaluation of SCUADs by means of comparison with mild chronic upper airway diseases...
  52. doi Development and implementation of guidelines in allergic rhinitis – an ARIA-GA2LEN paper
    Jean Bousquet
    University Hospital, Hopital Arnaud de Villeneuve, Montpellier Cedex 5, France
    Allergy 65:1212-21. 2010
    ..Guidelines must be updated as new management options become available or important new evidence emerges. Transparent reporting of guidelines facilitates understanding and acceptance, but implementation strategies need to be improved...
  53. doi Revisiting Desensitization and Allergen Immunotherapy Concepts for the International Classification of Diseases (ICD)-11
    Luciana Kase Tanno
    Hospital Sirio Libanes, Sao Paulo, Brazil Division of Allergy, Department of Pulmonology, University Hospital of Montpellier, Montpellier, France Pierre Louis Institute of Epidemiology and Public Health, Sorbonne Universités, Paris, France
    J Allergy Clin Immunol Pract 4:643-9. 2016
    ..We strongly believe that this review is a key instrument to support the allergy specialty identity into the ICD-11 framework and serves as a platform to perform positive quality improvement in clinical practice. ..
  54. doi MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis
    Jean Bousquet
    University Hospital, Montpellier, France MACVIA LR, Contre les Maladies Chroniques pour un vieillissement actif en Languedoc Roussillon, European Innovation Partnership on Active and Healthy Ageing Reference Site, Montpellier, France INSERM, VIMA Ageing and Chronic Diseases, Epidemiological and Public Health Approaches, Paris, and Université Versailles St Quentin en Yvelines, St Quentin en Yvelines, France Electronic address
    J Allergy Clin Immunol 138:367-374.e2. 2016
    ..A CDSS is currently being developed to optimize AR control. An algorithm developed by consensus is presented in this article. This algorithm should be confirmed by appropriate trials. ..
  55. pmc Dissemination of definitions and concepts of allergic and hypersensitivity conditions
    Luciana Kase Tanno
    Hospital Sirio Libanes, Sao Paulo, Brazil Division of Allergy, Department of Pulmonology, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier, France Sorbonne Universités, UPMC Paris 06, UMR S 1136, IPLESP, Equipe EPAR, 75013 Paris, France
    World Allergy Organ J 9:24. 2016
    ....
  56. doi Allergen Immunotherapy Outcomes and Unmet Needs: A Critical Review
    Davide Caimmi
    Division of Allergy, Department of Pulmonology, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, 371, av du Doyen Gaston Giraud 34295, Montpellier Cedex 5, France MACVIA LR, European Innovation Partnership on Active and Healthy Ageing Reference Site, University Hospital of Montpellier, 371, av du Doyen Gaston Giraud 34295, Montpellier Cedex 5, France
    Immunol Allergy Clin North Am 36:181-9. 2016
    ..These aspects still seem to be the main unmet need in the evaluation of AIT clinical outcomes in clinical trials. ..
  57. ncbi ERASM, a pharmacoepidemiologic survey on management of intermittent allergic rhinitis in every day general medical practice in France
    Pascal Demoly
    Service des Maladies Respiratoires, Hopital Arnaud de Villeneuve, CHU de Montpellier, France
    Allergy 57:546-54. 2002
    ..The actual management of intermittent allergic rhinitis is still little known about, despite the disease being very prevalent. We used a cross-sectional survey to address this issue in everyday general medical practice in France...
  58. ncbi Drug allergy diagnosis work up
    Pascal Demoly
    Maladies Respiratoires, INSERM U454, Hopital Arnaud de Villeneuve, CHU de Montpellier, F 34295 Montpellier, France
    Allergy 57:37-40. 2002
    ..These tools are currently being evaluated by the European Network of Drug Allergy, under the aegis of the EAACI drug hypersensitivity group of interest...
  59. ncbi Immunotherapy: clinical trials--optimal trial and clinical outcomes
    Philippe Jean Bousquet
    Clinique des Maladies Respiratoires, Hopital Arnaud de Villeneuve, Centre Hospitalier Universitaire, Montpellier, France
    Curr Opin Allergy Clin Immunol 7:561-6. 2007
    ..Although specific immunotherapy was introduced a century ago, very few trials meet the criteria for pivotal studies. The paper reviews the methods which should be used to investigate specific immunotherapy...
  60. doi Montelukast in guidelines and beyond
    Jean Bousquet
    Service des Maladies Respiratoires, Hopital Arnaud de Villeneuve, 371 Avenue Doyen Gaston Giraud, 34275 Montpellier, Cedex 5, France
    Adv Ther 26:575-87. 2009
    ..This review includes new studies that have not yet been considered in guidelines...
  61. ncbi Effects of carbamazepine and metabolites on IL-2, IL-5, IL-6, IL-10 and IFN-γ secretion in epileptic patients: the influence of co-medication
    Olivier Mathieu
    Département de Pharmacologie Médicale et Toxicologie, Centre Hospitalier Régional Universitaire de Montpellier, 191, Avenue Gaston Giraud, 34295 Montpellier Cedex 5, France
    Pharmacol Rep 63:86-94. 2011
    ....
  62. ncbi Cysteinyl-leukotriene release test (CAST) in the diagnosis of immediate drug reactions
    B Lebel
    Maladies Respiratoires, INSERM U454 - IFR3, CHU de Montpellier, Montpellier Cedex, France
    Allergy 56:688-92. 2001
    ..The efficiency of both tests was low. CONCLUSION: Thus, in most cases, the in vitro Cys-LT test has little or no diagnostic utility and is not superior to histamine release...
  63. ncbi Allergen-induced mediator release tests
    P Demoly
    Maladies Respiratoires INSERM U454, CHU de Montpellier, Cedex, France
    Allergy 58:553-8. 2003
    ..In this review, we will detail allergen-dependent histamine, tryptase, arachidonic acid metabolite, e.g. cysteinyl leukotrienes and 15-hydroxyeicosatetraenoic mediator release tests...
  64. ncbi Validation of the classification of ARIA (allergic rhinitis and its impact on asthma)
    P Demoly
    Unité d Explorations des Allergies, Service des Maladies Respiratoires, INSERM, Hopital Arnaud de Villeneuve, Montpellier Cedex, France
    Allergy 58:672-5. 2003
    ..Allergic rhinitis is commonly divided into seasonal and perennial rhinitis. The recent Allergic Rhinitis and its Impact on Asthma (ARIA) workshop proposes to replace these terms by intermittent vs persistent rhinitis...
  65. ncbi Relevance of the determination of serum-specific IgE antibodies in the diagnosis of immediate beta-lactam allergy
    C Fontaine
    Exploration des allergies Maladies Respiratoires and INSERM U454 IFR3, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier Cedex 5, France
    Allergy 62:47-52. 2007
    ..They can be explored by in vivo and/or in vitro tests. The measurement of serum-specific immunoglobulin E (IgE) presents several advantages: safety, simplicity, and availability to nonallergologist physicians...
  66. ncbi ARIA (Allergic Rhinitis and Its Impact on Asthma) classification of allergic rhinitis severity in clinical practice in France
    P J Bousquet
    Exploration des Allergies, Maladies Respiratoires, INSERM U454 IFR3, Hopital Arnaud de Villeneuve, CHU de Montpellier, Montpellier, France
    Int Arch Allergy Immunol 143:163-9. 2007
    ..The Allergic Rhinitis and Its Impact on Asthma (ARIA) workshop proposes a classification of allergic rhinitis severity. It does not take into account impairment in quality of life and treatment should be adapted accordingly...
  67. doi Allergic rhinitis management pocket reference 2008
    J Bousquet
    Allergic Rhinitis and its Impact on Asthma, Service des Maladies Respiratoires, Hopital Arnaud de Villeneuve, 34295 Montpellier Cedex 5, France
    Allergy 63:990-6. 2008
    ..This document will be a major resource in this educational program...
  68. doi Physician and patient survey of allergic rhinitis in France: perceptions on prevalence, severity of symptoms, care management and specific immunotherapy
    P Demoly
    Unité d Exploration des Allergies, INSERM U657 Hôpital Arnaud de Villeneuve, Montpellier, France
    Allergy 63:1008-14. 2008
    ..A telephone survey of patients and physicians in France was carried out to understand better the real and perceived advantages and inconveniences of this therapeutic approach...
  69. doi Updating Allergy and/or Hypersensitivity Diagnostic Procedures in the WHO ICD-11 Revision
    Luciana Kase Tanno
    Hospital Sirio Libanes, Sao Paulo, Brazil Division of Allergy, Department of Pulmonology, University Hospital of Montpellier, Montpellier, France Pierre Louis Institute of Epidemiology and Public Health, Sorbonne Universités, Paris, France
    J Allergy Clin Immunol Pract 4:650-7. 2016
    ....
  70. pmc Supporting the validation of the new allergic and hypersensitivity conditions section of the World Health Organization International Classification of Diseases-11
    Luciana Kase Tanno
    Hospital Sirio Libanes, São Paulo 01308 050, Brazil Division of Allergy, Department of Pulmonology, University Hospital of Montpellier, Montpellier, and Pierre Louis Institute of Epidemiology and Public Health, Sorbonne Universités, Paris, France
    Asia Pac Allergy 6:149-56. 2016
    ..All the efforts are being acknowledged by the Joint Allergy Academies...
  71. doi [Respiratory allergies]
    Anca Mirela Chiriac
    Hopital Arnaud de Villeneuve, Département de Pneumologie et Addictologie, INSERM U657, 34295 Montpellier Cedex 5, France
    Presse Med 42:395-404. 2013
    ..In terms of route of administration, sublingual immunotherapy represents a good alternative to subcutaneous immunotherapy, considering its proven efficacy and better safety profile...
  72. pmc Assessment of disease control in allergic rhinitis
    Pascal Demoly
    Allergy Division, Pulmonary Department, INSERM U657 EA2415, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier, France
    Clin Transl Allergy 3:7. 2013
    ..We conclude that there is a need for research in which severity is compared with control in terms of their effects on patient management...
  73. pmc Comprehensive allergy work-up is mandatory in cystic fibrosis patients who report a history suggestive of drug allergy to beta-lactam antibiotics
    Silvia Caimmi
    Allergy Unit, Deépartement de Pneumologie et Addictologie, Hopital Arnaud de Villeneuve, University Hospital of Montpellier and Inserm U657, 37, avenue du Doyen Gaston Giraud, 34295, Montpellier Cedex 5, France
    Clin Transl Allergy 2:10. 2012
    ..After a drug allergy work-up at best 20% of the selected patients are positive. However, these considerations have not been explored in cystic fibrosis patients for whom antibiotics are even more crucial...
  74. ncbi [Contribution of epidemiology to the prevention of drug allergies]
    Pascal Demoly
    Pneumologie et Addictologie, INSERM U657, Hopital Arnaud de Villeneuve, 371 Avenue du Doyen Gaston Giraud, 34295 Montpellier Cedex 5, France
    Bull Acad Natl Med 195:1335-42; discussion 1342-4. 2011
    ..This review examines the place of interventional epidemiology in the field of drug allergy, taking as examples both myorelaxant-induced anaphylaxis and abacavir-induced DRESS...
  75. ncbi Overexpression of the human glucocorticoid receptor alpha and beta isoforms inhibits AP-1 and NF-kappaB activities hormone independently
    Claire Gougat
    Institut National de la Santé et de la Recherche Médicale U454 IFR3 and Service des Maladies Respiratoires, CHU de Montpellier, 34295 Montpellier Cedex 5, France
    J Mol Med (Berl) 80:309-18. 2002
    ..This property was not shared by the closely related mineralocorticoid receptor. Our results suggest that overexpression of either GRalpha or GRbeta may have an anti-inflammatory effect...
  76. ncbi IFN-gamma-mediated inhibition of human IgE synthesis by IL-21 is associated with a polymorphism in the IL-21R gene
    Jerome Pene
    Institut National de la Sante et de la Recherche Medicale, Unite 454, Centre Hospitalier Universitaire St Eloi, Montpellier, France
    J Immunol 177:5006-13. 2006
    ....
  77. ncbi [Drug allergy and hypersensitivity. Risk factors]
    Pascal Demoly
    Exploration des Allergies Maladies Respiratoires, INSERM, Hopital Arnaud de Villeneuve, avenue du Doyen Gaston Giraud, 34295 Montpellier 5, France
    Bull Acad Natl Med 190:1733-42; discussion 1742-4. 2006
    ..An ongoing study by our group points to a role of polymorphisms within the IL-10 promoter and in the IL-4Ralpha gene in immediate reactions to beta-lactams...
  78. ncbi Selective hypersensitivity to pidolate
    N Raison-Peyron
    Maladies Respiratoires, INSERM U454 IFR3, Hôpital Arnaud de Villeneuve CHU Montpellier, France
    Allergy 57:53-4. 2002
  79. ncbi The accuracy of the diagnosis of suspected macrolide antibiotic hypersensitivity: results of a single-blinded trial
    S Benahmed
    Maladies Respiratoires, INSERM U454, Hopital Arnaud de Villeneuve, CHU de Montpellier, 34295 Montpellier Cedex 5, France
    Allergy 59:1130-3. 2004
  80. ncbi Latex is not essential in a standardized skin prick test battery
    P J Bousquet
    University Hospital, Allergy, Montpellier, France
    Allergy 60:407-8. 2005
  81. ncbi Isolated urticaria to ondansetron and successful treatment with granisetron
    P J Bousquet
    Exploration des Allergies, Maladies Respiratoires, INSERM U454, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, 34295 Montpellier Cedex 5, France
    Allergy 60:543-4. 2005
  82. ncbi The diagnosis of asthma using a self-questionnaire in those suffering from allergic rhinitis: a pharmaco-epidemiological survey in everyday practice in France
    P Demoly
    Exploration des allergies Maladies Respiratoires and INSERM U454 IFR3, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier Cedex, France
    Allergy 61:699-704. 2006
    ....
  83. ncbi IL-10 promoter and IL4-Ralpha gene SNPs are associated with immediate beta-lactam allergy in atopic women
    L Guglielmi
    INSERM U454, CHU Arnaud de Villeneuve, Montpellier
    Allergy 61:921-7. 2006
    ..Allergic reactions to beta-lactam antibiotics represent the most frequent cause of immunological drug reactions...
  84. ncbi Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?
    H Peyriere
    Department of Medical Pharmacology, University Hospital of Montpellier, Hopital Lapeyronie, 971 avenue du doyen Gaston Giraud, 34295 Montpellier Cedex 5, France
    Br J Dermatol 155:422-8. 2006
    ....
  85. ncbi Anaphylactic shock after oral intake and contact urticaria due to polyethylene glycols
    H B Co-Minh
    Dermatology Unit, St Eloi Hospital 80, avenue Augustin Fliche, 34295 Montpellier Cedex 5, France
    Allergy 62:92-3. 2007
    ..We reported an anaphylaxis after oral intake and contact urticaria due to polyethylene glycols...
  86. doi Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)
    J Bousquet
    University Hospital and INSERM, Hopital Arnaud de Villeneuve, Montpellier, France
    Allergy 63:8-160. 2008
  87. doi Important questions in Allergy: 1--drug allergy/hypersensitivity
    P Demoly
    Exploration des Allergies Inserm U657, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier, France
    Allergy 63:616-9. 2008
  88. doi Spreading and impact of the World Health Organization's Allergic Rhinitis and its impact on asthma guidelines in everyday medical practice in France. Ernani survey
    P Demoly
    Allergy Department, University Hospital of Montpellier and Inserm U657, Hopital Arnaud de Villeneuve, 34295 Montpellier cedex 05, France
    Clin Exp Allergy 38:1803-7. 2008
    ..The aim of this study was to determine the spreading level of the WHO-ARIA (World Health Organization's Allergic Rhinitis and its Impact on Asthma) guidelines among the medical community and their influence on medical practices...
  89. ncbi Severe anaphylaxis to bee venom immunotherapy: efficacy of pretreatment and concurrent treatment with omalizumab
    C Galera
    Allergy and Respiratory Diseases Unit, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier, France
    J Investig Allergol Clin Immunol 19:225-9. 2009
    ..AntiIgE has provided a treatment option for patients with severe IgE-mediated allergic disease that is difficult to treat. This case suggests that omalizumab may be able to prevent anaphylaxis during immunotherapy...
  90. ncbi [GA2LEN (Global Allergy and Asthma European Network)]
    J Bousquet
    CHU, Hopital Arnaud de Villeneuve, INSERM U780, Montpellier, France
    Rev Mal Respir 26:577-86. 2009
    ..The major achievements of GA2LEN are reported in this paper...
  91. doi [Allergy to neuromuscular blocking agents]
    Anca Mirela Chiriac
    Centre Hospitalier Universitaire de Montpellier, Hopital Arnaud de Villeneuve, Département de Pneumologie et Addictologie, unité exploration des allergies, 34295 Montpellier, France Sorbonne Universités, UPMC Paris 06, UMR_S 1136, Institut Pierre Louis d Epidémiologie et de Santé Publique, Equipe EPAR, 75013 Paris, France Electronic address
    Presse Med 45:768-73. 2016
    ..In cases of true allergy, assessing cross-reactivity to other NMBAs is mandatory. The cross-sensitization hypothesis is presently being investigated and if confirmed, it could allow primary prevention measures to be implemented. ..
  92. doi The Potential Role of Allergen Immunotherapy in Stepping Down Asthma Treatment
    Pascal Demoly
    Department of Pulmonology, Division of Allergy, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier, France Sorbonne Universités, Paris, France
    J Allergy Clin Immunol Pract . 2016
    ..It is important to further explore this effect so that affected individuals can benefit from this treatment...
  93. doi Phenotypical characterization of children with hypersensitivity reactions to NSAIDs
    Mathias Cousin
    Unité d Allergologie, Département de Pneumologie et Addictologie, Hopital Arnaud de Villeneuve, CHRU de Montpellier, Montpellier, France
    Pediatr Allergy Immunol 27:743-748. 2016
    ....
  94. pmc Patient engagement and patient support programs in allergy immunotherapy: a call to action for improving long-term adherence
    Pascal Demoly
    Department of Pulmonology, Division of Allergy, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier, France Sorbonne Universités, UPMC Paris 06, UMR S 1136, IPLESP, Equipe EPAR, Paris, France
    Allergy Asthma Clin Immunol 12:34. 2016
    ..We conclude that multistakeholder PSPs (combining patient-, provider and society-based actions) must now be developed and tested with a view to increasing adherence, efficacy and safety in the field of AIT. ..
  95. ncbi 300 IR HDM tablet: a sublingual immunotherapy tablet for the treatment of house dust mite-associated allergic rhinitis
    Pascal Demoly
    a Department of Pulmonology Division of Allergy, Hopital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier and Sorbonne Universités, UPMC Paris 06, UMR S 1136, IPLESP, Equipe EPAR, Paris, France
    Expert Rev Clin Immunol 12:1141-1151. 2016
    ..Clinical efficacy is maintained for 1 year after treatment is stopped...
  96. pmc Drug provocation tests: up-date and novel approaches
    Anca Mirela Chiriac
    Allergy Unit, Hopital Arnaud de Villeneuve, 371 Avenue du Doyen Giraud, Montpellier, 34295, France
    Allergy Asthma Clin Immunol 9:12. 2013
    ..Novel (or sometimes, simply renewed) approaches arise, awaiting to be either validated or refuted in larger studies in the future. Instead of covering the whole topic of DPTs, this paper will address these recent and challenging aspects...
  97. ncbi JLP5B9: new monoclonal antibody against polysialylated neural cell adhesion molecule is of value in phenotyping lung cancer
    M Del Rio
    CNRS UMR 9921, Centre de Recherche en Cancerologie, CRLC Val d Aurelle, Montpellier, France
    J Immunol Methods 233:21-31. 2000
    ..This mAb deserves further investigation to evaluate its potential as a tool for serodiagnosis of lung cancer...
  98. ncbi Long-term safety and efficacy of nevirapine tolerance induction
    D Messaad
    Maladies Respiratoires, Hopital Arnaud de Villeneuve, Montpellier University Hospital, France
    Clin Exp Allergy 32:733-5. 2002
    ..In non-serious cases, tolerance induction can be proposed...
  99. ncbi Immunotherapy with keyhole lampet hemocyanin-conjugated decapeptide vaccine in cypress pollen allergy
    P Demoly
    Maladies Respiratoires, Hopital Arnaud de Villeneuve, Montpellier, France
    Clin Exp Allergy 32:1071-6. 2002
    ..Cupressaceae pollen allergy is a world-wide pollinosis but immunotherapy has rarely been tested. Immunotherapy is usually allergen-specific but new forms may be targeted towards IgE...
  100. ncbi Prick tests to aeroallergens: is it possible simply to wipe the device between tests?
    V Piette
    Maladies Respiratoires, INSERM U454 IFR3, Hopital Arnaud de Villeneuve, CHU de Montpellier, France
    Allergy 57:940-2. 2002
    ....
  101. ncbi [Skin testing with respiratory allergens: which techniques, which extracts, which battery?]
    V Piette
    Maladies Respiratoires, INSERM U454 IFR3, CHU de Montpellier, Montpellier, France
    Rev Mal Respir 19:529-31. 2002